I am pleased to announce that there have been notable advances in the LEODOR trial (Repetitive Levosimendan infusions for patients with advanced chronic heart failure), a randomised, double-blind, placebo-controlled multicentre study sponsored by the University of Innsbruck and supported by a grant from Orion Pharma.
The recent achievements include:
On the administration and communication side, LEODOR is now represented online by its own website (http://leodortrial.com/) which proves a wealth of information for everyone with an interest in the conduct and progress of the study and regular updates on recruitment. The “For Patients” page addresses key questions such as:
While the “For Investigators” page summarises the aims, design and eligibility criteria for LEODOR and provides additional technical and professional information on subjects including Trial Synopsis, Site Evaluation and Patient Consent through a suite of downloadable PDFs (via http://leodortrial.com/#investigators). The site also offers visitors a photo galley of the 14 principal investigators and a range of opportunities to contact the LEODOR team, which in the fullness of time will include tweets posting significant milestones in the progress of the trial. Go Team LEODOR!
Professor Gerhard Pölzl reports primary results from the LION-HEART study in the management of advanced heart failure where among secondary endpoints, patients treated with levosimendan experienced a reduction in the rate of HF-related hospitalisation compared with placebo.
Professor Gerhard Pölzl highlights Hospitalisation for the management of acute decompensation being a critical moment in the trajectory of heart failure (HF) and one that has gloomy prognostic implications for many patients.
Professor Gerhard Pölzl discusses the interplay between the acutely compromised heart and the kidneys and how the optimal treatment for individual cases is complex.
Professor Gerhard Pölzl discusses the Heart Failure Association of the European Society of Cardiology annual meeting, where several sessions were held on the use of levosimendan in heart failure.
The HFA-ESC has issued a fresh position paper [Crespo-Leiro MG et al. Eur J Heart Fail. 2018 May 27. doi: 10.1002/ejhf.1236]. Here’s our first take on some highlights.
If we had a way to reduce the risk of life-threatening complications after cardiac surgery would we use it? Of course we would. It is for reason that this blog post highlights the recent work of Dr. Qiang and colleagues. See the details here.
Professor Gerhard Pölzl highlights the LION-Heart and LAICA clinical trials.
Professor Cynthia M Dougherty and colleagues outline an array of options for the treatment of advanced heart failure (HF) that create – quite reasonably – the impression that we are in a golden age of therapeutic possibilities for this difficult condition.
Thoughts from the expert meeting organised by the Heart Failure Clinic, Attikon University Hospital, 2018.
Alternatively login via
Back to epgonline.org